Physician profile
Concepcion Crowe
NPI 1184382590
$4,415.01
in general payments reported to CMS, 2019-2025
18 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $589 · 2023: $950 · 2024: $804 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $706.74 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $565.11 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $560.28 | 2022-2025 | Descovy, Yeztugo |
| Vanda Pharmaceuticals INC. | $520.84 | 2022-2025 | Fanapt |
| Abbvie INC. | $499.86 | 2022-2025 | |
| Lilly USA, LLC | $306.48 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $304.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $248.10 | 2022-2025 | |
| Axsome Therapeutics, INC. | $233.32 | 2025 | Auvelity |
| Abiomed | $105.61 | 2023 | Impella |
| Janssen Products, LP | $100.15 | 2023 | Symtuza |
| Janssen Biotech, INC. | $64.20 | 2023 | Symtuza |
| Viiv Healthcare Company | $62.72 | 2024-2025 | Dovato, Rukobia |
| Pfizer INC. | $59.50 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $35.55 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $14.48 | 2023 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $13.57 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Concepcion Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.